Key Takeaways
- Capacity unlocks the story: DDC Line 2 went live in September, immediately doubling sterile production days, and Line 3 is now on-site. The second half is expected to be stronger, and the FY28 target of $400 mn revenue / $160 mn EBITDA was reaffirmed.
- Semaglutide momentum is building: Partner Hikma launched the first generic in Saudi Arabia, Dr. Reddy's API supply has commenced for a Canada relaunch, and management sees Canada and Brazil markets reaching 4–6x current levels.
- Biologics funnel is at an all-time high: Two end-to-end projects were onboarded from a U.S. biotech, plus a new program for a top animal-health company. Commercial revenues, which are a different order of magnitude, begin FY29.
- Working capital swelled on temporary factors: Trade receivables rose as shipping disruptions added 45–60 days to cycle times, but management calls this a timing issue that should normalize within a quarter or two.
- What to watch next quarter: The pace of Line 2's ramp toward 225–230 sterile days, the Dr. Reddy's Canada relaunch, and whether the shipping-related receivables buildup begins to reverse.
DDC Capacity: The Near-Term Growth Engine
- Line 2 live, Line 3 imminent: The second cartridge line began running commercial batches in September, immediately doubling total sterile production days. The third line has completed its factory acceptance test in Germany and is now at site ready for qualification.
- Ramp-up expected to be fast: Management expects Line 2 to reach 225–230 sterile days fairly rapidly given robust demand, and Line 3 is slated to follow the same pattern once it goes live, probably in Q4 FY27 or early FY28.
- What the capacity unlocks: The new lines enable MSAs for existing customers that were pending and onboarding of new customers, neither of which had been possible for the last year due to capacity constraints.
- End-to-end differentiation: Each line is backed by full cartridge filling, assembly, labeling, packaging and cold chain under one roof, a combination management says differentiates OneSource globally, not just in India.
- DDC contribution trajectory: DDC will be a strong contributor to H2 FY27 and remain a very strong contributor to FY28 numbers. Management declined to quantify the FY28 DDC sales figure when pressed.
Sharma: "And this is not just the filling capacity. I think that's what is important to highlight here and what really differentiates OneSource from every other CDMO is that every one of our lines are backed by full end-to-end capabilities, whether it is not only cartridge filling, but assembly, labeling, packaging and so on, including cold chain all under one roof. And this differentiates us not only in India, but even globally."
Semaglutide: Supply-Constrained, Not Demand-Constrained
- Hikma's Saudi launch: The partner launched the first generic semaglutide in Saudi Arabia, expanding OneSource's footprint in an off-patent market. Management called it a very significant launch.
- Dr. Reddy's back on track: API supply has commenced, which will enable a relaunch in Canada and launches across multiple other markets where Dr. Reddy's already holds approval. Supplies are expected to start within the current quarter, with additional market approvals expected over the next two quarters.
- Canada and Brazil poised to surge: Management expects these markets to reach 4–6x current levels. Multiple customers are waiting for Brazil approvals, and some have publicly announced approvals expected in the next quarter or two.
- The structural tailwind: The product was always constrained by supply rather than demand, and markets that are now off-patent are opening up sequentially. The U.S., the largest market, will open later.
Sharma: "This was a product which was always constrained by supply rather than the demand, whether it is the markets which are the largest in the world like U.S. and Europe, all these other markets which are now available off patent..."
Biologics: Building the Post-FY28 Story
- Funnel at an all-time high: The biologics RFP funnel is at its highest ever, with multiple projects in advanced stages. Two end-to-end development-to-commercialization projects were onboarded from a U.S. biotech, and an additional new program was secured for a top global animal-health company, an existing customer.
- "Gene to device" positioning: Management attributes the wins to an integrated offering that very few CDMOs provide, combined with India's growing position as a trusted hub for global biologics and biosimilar development and manufacturing.
- Revenue profile shift ahead: All biologics revenue during the guidance period is MSA, meaning pre-approval R&D services. Commercial revenues start from FY29 onwards and are of a very different order of magnitude compared to comparable small molecules.
- No specific molecule disclosure: When asked about participation in KEYTRUDA across biosimilar partnerships, management declined to comment on specific molecules, stating only that with all customers they have some of the largest products in the biosimilar space.
Sharma: "These wins, whether the U.S. or Europe, these really reflect the integrated offering, which we have, which we call from gene to device in biologics, which again, very few CDMOs offer and the fact that India's growing position as a trusted hub of global biologics biosimilar development as well as manufacturing."
Base Business & Injectables Expansion
- Injectables and softgel base business grew: Both segments grew last quarter with multiple launches across several markets, including the U.S., Europe and emerging markets. A total of 12 launches occurred this season across soft gelatin and injectables.
- Planned shutdown underway: An injectables site shutdown started at the back end of Q2. New capacity, including prefilled syringes and new lyophilization capacity, will be available from Q3 FY27 onwards.
- Softgel greenfield planned: A new greenfield site will add significant new capacity and allow entry into the containment and high-potent softgels modality. No timeline was given.
- Growth beyond FY28 from base business: Injectable capacity will fill over the next 2–3 years, and the new soft gelatin line plus the high-potent softgels modality will contribute. Management declined to guide on a growth rate beyond FY28, stating the outlook will be provided during FY28.
Margins, Costs & Operating Leverage
- Operating leverage visible: EBITDA growth outpaced revenue growth in Q2 and the first half, demonstrating the inherent operating leverage in the business as incremental cost is very limited compared to incremental revenue.
- Employee cost build is deliberate: The steady increase in employee costs over the last 5–6 quarters reflects the ramp-up of specialized capability at Unit 2, the flagship site, which is expanding capacity 2–3x within the year. These are high-level quality-observation roles, and the increase is on track, not a surprise.
- Consumables vary with activity: Consumables cost depends on activity levels: fresh batches, engineering batches and volume ramp-ups cause quarter-to-quarter variation.
- Pricing model is volume-based, not market-based: Realizations have not seen a major shift. When batch sizes increase in the sterile business, the cost of manufacturing per unit comes down, and savings are shared with customers in what management calls a win-win arrangement.
- Raw material is mostly pass-through: Geopolitical developments have implications for fuel, freight costs and shipping line availability, but the P&L impact is limited because most raw material cost is passed through to customers.
Sharma: "The very fact that when there is an increase in batch sizes in a sterile business, the cost of manufacturing per unit comes down, and we are happy to share the savings there with our customers. So it's a fairly win-win."
Working Capital & Balance Sheet
- Receivables swelled on two factors: Trade receivables increased in H1 FY27 due to shipping line delays and container availability issues adding 45–60 days to cycle times, plus significantly higher volumes in recent quarters. Management stressed there is no quality issue on the receivables.
- Temporary, not structural: The shipping-related impact is described as a timing issue only, expected to normalize within a quarter or two.
- Debt and ROCE outlook: Debt is anticipated to remain under 1.5x EBITDA, and ROCE is anticipated in the high 20s by the end of FY28.
- Effective tax rate: Current ETR levels are expected to continue through FY28, at least until Q3 FY28, due to utilization of brought-forward losses.
Bhagania: "I do believe that it is not structural. It is temporary, and it is only a timing impact. Hopefully, within a quarter or 2, we should start seeing this getting normalized."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY28 revenue and EBITDA | $400 mn revenue, $160 mn EBITDA | FY28 |
| All 3 DDC lines fully operational | Lines 1, 2 and 3 available for full-year contribution | FY28 |
| Line 3 commercialization | Qualification and commercial start; every effort being made for Q4 FY27 | Q4 FY27 or early FY28 |
| Line 2 and Line 3 utilization | Each line to reach 225–230 sterile days per year | Rapidly after qualification |
| Dr. Reddy's supply restart | API supply commenced; first to Canada, then multiple other markets | Within current quarter (Q3 FY27) |
| Dr. Reddy's additional market approvals | Approvals in additional markets beyond those already held | Next 2 quarters |
| Injectables new capacity | Prefilled syringes and new lyophilization capacity available | Q3 FY27 onwards |
| Working capital normalization | Shipping-related cycle-time impact of 45–60 days to reverse | Within 1–2 quarters |
| Effective tax rate | Current ETR levels sustained | Through at least Q3 FY28 |
| Debt ceiling | Under 1.5x EBITDA | Through FY28 |
| ROCE target | High 20s | By end of FY28 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | >₹500 cr, +37% YoY and +15% QoQ |
| EBITDA | +53% YoY, +32% QoQ |
| EBITDA margin | 32%, expanded >400 bps QoQ |
| First-half EBITDA growth | +47% YoY |
| FY28 revenue guidance | $400 million, reaffirmed |
| FY28 EBITDA guidance | $160 million, reaffirmed |
| DDC sterile production days | Doubled with Line 2 operational from September |
| Line 2 batch size capability | Up to 750 liters; customers ramping to 500 liters |
| Line 1 output | ~50,000–55,000 pens/day at 200 liters |
| Line 2 output at 500 liters | ~120,000–130,000 pens/day |
| Steady-state DDC mix target | 75% commercial, 25% MSA per line |
| Softgel capacity utilization visibility | 80%+ |
| India semaglutide monthly units | >200,000 as of September, up from ~20,000–25,000 pre-patent expiry |
| Canada semaglutide market | ~1.6–1.7 crore units post-genericization, continuing to grow |
| Currency fluctuation impact | ~$350k, reported separately in financials |
| Debt level target | Under 1.5x EBITDA |
| ROCE target by end of FY28 | High 20s |